A Multicentric Brazilian Investigative Study of Copy Number Variations in Patients with Congenital Anomalies and Intellectual Disability

J. R. M. Ceroni, R. L. Dutra, R. S. Honjo, J. C. Llerena Jr., A. X. Acosta, P. F. V. Medeiros, M. F. Galera, É. A. Zanardo, F. B. Piazzon, A. T. Dias, G. M. Novo-Filho, M. M. Montenegro, F. A. R. Madia, D. R. Bertola, J. B. de Melo, L. D. Kulikowski & C. A. Kim

Genomic imbalances are the most common cause of congenital anomalies (CA) and intellectual disability (ID). The aims of this study were to identify copy number variations (CNVs) in 416 patients with CA and ID from 5 different genetics centers within 4 different states by using the Multiplex Ligation-dependent Probe Amplification (MLPA) technique and to apply the chromosomal microarray (CMA) methodology in selected cases. The samples were analyzed by MLPA kits P064, P036, P070 and P250. Positive results were found in 97/416 (23.3%) patients. CMA was applied in 14 selected cases. In 6/14 (42.85%) patients, CMA detected other copy number variations not detected by the MLPA studies. Although CMA is indispensable for genotype refinement, the technique is still unfeasible in some countries as a routine analysis due to economic and technical limitations. In these cases, clinical evaluation followed by karyotyping and MLPA analysis is a helpful and affordable solution for diagnostic purposes.
known pathogenicity in the literature, pattern of inheritance, and the influence of the imbalance over the expression of the other allele, as there is higher susceptibility of other genomic rearrangements in these patients.

Until the advent of molecular techniques such as fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), Multiplex Ligation Probe-dependent Amplification (MLPA), and chromosomal microarray (CMA), small CNVs were not detected. Consistent with this fact, the literature has shown a higher diagnostic usage of cytogenomic techniques over G-band karyotyping in patients with CA and ID, with a 9–30% detection by MLPA, depending on the combination of kits and previous screening, and 20% by chromosomal microarray (CMAs) versus 5% with G-band karyotyping.

Despite the fact that some pathogenic CNVs cause syndromes with a clinically recognizable phenotype, such as the 7q11.23 microdeletion (Williams syndrome) and the 22q11.23 microdeletion (DiGeorge syndrome), that could be investigated by a specific genetic test (e.g., FISH), the vast majority of small CNVs produce a nonspecific phenotype, for which CMA is the recommended genetic test. Since 2008, the substitution of karyotyping for CMA has been recommended by both the First International Workshop on Uniform Cytogenetic Arrays and Shared Databases and the Canadian Society for Medical Laboratory Science. Therefore, CMA is the gold standard technique for the detection of small CNVs, defined as fragments larger than one kilobase (1 Kb), with a distinct number of copies in the genome, and not detectable by karyotyping (<5 Mb). CNVs in the human genome are the main cause of CA (2–3% of live births) and ID.

While very valuable in routine diagnosis, CMA is not available in the public healthcare systems of underdeveloped countries due to a lack of economic and human resources. Therefore, the establishment of less expensive alternatives based on the patients' clinical presentation and cost-benefit methodology are of great interest in clinical practice. This is particularly true for congenital heart defects, which are the most prevalent category of birth defects. The application of MLPA studies in this group of patients provides a high diagnostic yield, suggesting a good cost-benefit.

Thus, in order to determine the presence of CNVs in Brazilian patients with CA, ID and/or neurodevelopmental delay whose peripheral blood G-banding karyotyping had normal results, we used a combination of MLPA kits, and CMA was applied only in selected cases. We also evaluated the efficiency and applicability of this cytogeneric approach in the investigation of a large series of patients undergoing clinical genetic follow-up.

### Results

Molecular analysis by MLPA detected pathogenic CNVs in 97/416 patients (23.3%). In 59 (14.1%) patients, kit P064 was positive; in 45 (10.8%) patients, kit P036 was positive; in 43 (10.3%) patients, kit P070 was positive; and in 4 (0.9%) patients, kit P250 was positive. Table 1 is illustrative of these results and shows additional information of the patients.

Recurrent chromosomal imbalances were identified as microdeletion 22q11.23 (DiGeorge syndrome) in 26 patients, including 23 with the typical 3 Mb deletion and 3 with atypical deletions. Microdeletion 7q11.23 (Williams-Beuren syndrome) was identified in 20 patients, microdeletion 1p36 was identified in 6 patients, and microdeletion 4p16.3 (Wolf-Hirschhorn syndrome) was identified in 5 patients. Other imbalances found are shown in Table 2. In 24/97 (24.7%) patients, the MLPA detected more than 1 CNV (Table 2). Figure 1 demonstrates the results of a patient with two concurrent CNVs.

CMA studies were performed in selected 14 patients in order to better delineate genotype. These patients were selected by two main criteria, in addition to the availability of financial resources: presence of more than one CNV detected by MLPA and/or atypical CNVs. In 6/14 (42.8%) patients, CMA identified additional CNVs not detected by MLPA, which are described as below and shown in Table 3.

In three patients, array confirmed the CNVs found in MLPA (microdeletion 2q37 and microduplication 5q35.3) and demonstrated a benign duplication of 241 Kb in chromosome 18q12 that could not be detected by the combination of MLPA kits used because there were no probes at the specific regions.

In one patient, array confirmed the CNVs found by MLPA (microdeletion 2q37 and microduplication 5q35.3 – shown in Fig. 2) and detected an additional two CNVs: one deletion of 136.7 Kb in chromosome 12q13 and a duplication of 241 Kb in chromosome 18q12, both classified as benign. Neither of these deletions could be detected by the combination of MLPA kits utilized.

One patient had MLPA results demonstrating two microduplications in chromosome X (Xp22 and Xq28), and a microdeletion of chromosome 7q11.23; however, array results of this patient showed a complex rearrangement in chromosome 7q11.23, two duplications in chromosome X (243 Kb in Xq28 and 2.5 Mb in Xp22.33) and an additional CNV not detected by MLPA, a 60-Kb microdeletion on chromosome 13q31.3.

| MLPA Kit | Positive Results | Mean Age | Sex |
|----------|------------------|----------|-----|
| P036     | 47/416 (11.3%)   | N/A      | N/A |
| P064     | 59/416 (14.2%)   | N/A      | N/A |
| P070     | 47/416 (11.3%)   | N/A      | N/A |
| P250     | 4/416 (0.9%)     | N/A      | N/A |
| P036 + P070 | 34/416 (8.2%)  | N/A      | N/A |
| P036 + P070 + P064 | 13/416 (3.1%) | N/A      | N/A |
| TOTAL    | 97/416 (23.3%)   | 10.5 years | 172 (41.3%) males/244 (58.7%) females |

Table 1. Genomic imbalances found by MLPA within the use of different kits.
One patient had MLPA results that showed a microdeletion in chromosome 1p36, and CMA results showed a complex rearrangement in chromosome 1p36.3, two microdeletions of 1.89 Mb and 973 Kb, and a microduplication of 167 Kb.

Parental studies revealed CNVs were de novo in 59/97 patients (60.8%), inherited in 8 (8.2%) patients and classified as of unknown origin in 30 (31%) patients due to the absence of a parental DNA sample.

**Discussion**

In patients with isolated ID, subtelomeric CNVs can be present in up to 3–6% of cases, and when ID is associated with any CA, CNVs are found in up to 10% of cases. In patients with congenital heart diseases, recent work has shown that CNVs are present in 25.5% of patients. Genetic syndromes that present with congenital heart defects were prevalent in our cohort, including microdeletion 22q11.2 in 26 patients (22 with the typical deletion) and Williams-Beuren syndrome in 20 patients. Both of these syndromes are characterized by congenital heart defects - conotruncal malformation and supravalvar aortic stenosis, respectively.

Subtelomeric regions are more likely to be involved in rearrangements because only one chromosomal breakpoint is required. Subtelomeric chromosomal imbalances found by the combination of MLPA kits P036 and P070 were found in 47 (11.3%) patients, similar to the numbers reported in the literature. Vries et al. demonstrated that 4.8% of 2500 patients with ID had CNVs in subtelomeric regions. Several studies have reported pathogenic variants in 2.6% of patients.

A total of 14.1% of patients (59/416 patients) tested positive with P064, higher than that observed in the literature. Kirchhoff et al. showed that 6% of 258 patients with ID were positive when evaluated by MLPA kit P064. This finding reinforces the fact that higher diagnostic sensitivities are obtained when the cohort consists of patients with congenital heart defects that have had previous assessment by clinical geneticists.

| Chromosomal imbalance detected by MLPA | Number of patients |
|----------------------------------------|--------------------|
| microduplication 2p25.3/microdeletion 4q35.2 | 1 |
| microdeletion 2q37.3/microduplication 5q35.3 | 5 |
| microduplication 3q29/microdeletion 9p24.3 | 1 |
| microdeletion 4p16.3/microduplication 8p23.3 | 1 |
| microdeletion 4q35 | 2 |
| microdeletion 4q35.2/microduplication 5q35.3 | 1 |
| microduplication 4q35.2/microdeletion 7q36.3 | 1 |
| microduplication 4q35.2/microduplication Xq28 | 1 |
| microdeletion 5p15.3 | 3 |
| microduplication 5p15.3/microduplication 14q12.3 | 1 |
| microduplication 5p15.3/microdeletion Xq28 | 1 |
| microduplication 5q | 3 |
| microdeletion 7p22.3/microduplication 12q24.3 | 1 |
| microduplication 7q11.23 | 3 |
| microdeletion 7q11.23/microduplication Xp22/microduplication Xq28 | 1 |
| microdeletion 9p24.3/microduplication 18q23 | 2 |
| microduplication 9p24.3 | 2 |
| microduplication 11p15.5 | 1 |
| microduplication 12p13.33 | 1 |
| microduplication 12q24.3/microduplication 15q11.2 | 1 |
| microduplication 15q26.3/microdeletion Xq28 | 1 |
| microdeletion 15q11 | 1 |
| microduplication 15q11 | 1 |
| microduplication 16q24.3 | 1 |
| microdeletion 17p11 | 2 |
| microdeletion 17p13.3/microduplication 17q25.3 | 1 |
| microdeletion 20q13 | 1 |
| microduplication 22q11.1 | 3 |
| microduplication 22q13.3 | 1 |
| microdeletion 17p13.3/microduplication 17q25.3 | 1 |
| microdeletion 20q13 | 3 |
| microduplication 22q11.21/microdeletion 22q13.33 | 1 |
| microdeletion Xp22.12/microduplication Xp22.31 | 1 |
| microdeletion Xp22.31/microduplication Xq28 | 1 |
| microduplication Xp22.31 | 1 |
| microduplication Yp11.21/microduplication Yq28 | 1 |
| microduplication Yp11.21 | 1 |

Table 2. Other chromosomal imbalances detected by MLPA technique.
The combination of kits P064, P036 and P070 in our study was positive in 97/416 (23.3%) patients. In our previous study of 261 patients by Jehee et al.\textsuperscript{10}, pathogenic imbalances were found in 21.8% patients. Both results show higher sensitivity when compared to other studies\textsuperscript{11,25}.

In our study of 416 patients from five different genetic centers, MLPA confirmed the diagnosis in 97 (23.3%) patients and was complemented with CMAs in 14 selected patients (Table 3). Indeed, despite the huge evolution of genomic testing in recent years, a detailed clinical evaluation retains tremendous significance because it allows for the proper selection of patients and genetic test, thereby raising the cost-benefit ratio. In underdeveloped countries, this is essential to the sustainability of the healthcare system.

CMA leads to a better characterization of genomic imbalances, genotype-phenotype correlation, and the identification of candidate genes to relevant phenotypes\textsuperscript{26}. Oligoarrays have been used in genomic evaluation of patients with ID and CA. Because most oligoarrays detect submicroscopic CNVs throughout the whole genome\textsuperscript{27,28} with high resolution (~0.7 Kb depending on the platform and probe distribution within the genome)\textsuperscript{29–31}, these investigations have shown that submicroscopic chromosomal imbalances affect transcription dosage, sequence, structure and function of different genes\textsuperscript{7,32}. Arrays also have the capability of detecting complex rearrangements.

Although precise breakpoints were only detectable with CMA, eight (57.14%) patients did not show other CNVs. Of the six (42.86%) patients with discrepant results, 4 had CNVs that could not be detected by the MLPA kits used but were all classified as benign. Therefore, despite the fact that without CMA these CNVs would have gone unnoticed, none had clinical significance. The two cases in which clinically relevant CNVs were detected by CMA and not by MLPA were due to complex chromosomal rearrangements that are not expected to be detectable by MLPA.

The array of one patient, whose clinical features resembled Williams-Beuren syndrome but with atypical behavior and karyotype 46, XYY [20], showed complex rearrangements in chromosomes 7 and 13 and a small deletion in the X chromosome\textsuperscript{33,34}.

One patient had conflicting results, in which MLPA detected duplication in chromosome 7q11.23, but CMA demonstrated only a benign microdeletion of 273.6 Kb in chromosome 18p11.21. One possibility for this discrepancy is sample exchange. Further studies have not been performed in this patient.

In our patients, CNVs were inherited in 8 cases, and none of the carriers presented relevant symptoms. Incomplete penetrance of CNVs, broad phenotype expressivity\textsuperscript{10,26}, imprinting effects, and a second mutation not detectable by microarray on the other allele are plausible explanations for lack of clinical findings.
In summary, considering the relative low cost of the technique and the detection of alterations in 23.3% of patients, the investigation of CNVs in our patients with CA and ID by multiplex ligation-dependent probe amplification by the combination of kits P036, P070, P064, and P250 provided valuable results. Therefore, we suggest that in countries where CMA is still unfeasible as a routine analysis, clinical evaluation followed by karyotyping and MLPA analysis using different kits is still a helpful and affordable solution in particularly within a group of patients with congenital heart defects.

Materials and Methods

A total of 416 patients were enrolled in this prospective study, including 172 males and 244 females. The age of the patients varied from 8 months to 28 years (mean of 10.5 years).

Inclusion criteria were patients with congenital anomalies, neurodevelopmental delay or intellectual disability, whose G-banding karyotyping from peripheral blood had a normal result or did not explain the clinical findings of the patient. Parental genetic material was also analyzed when necessary.

All patients were clinically evaluated at genetics facilities from five different health centers in Brazil encompassing four different states between 2011 and 2014. All research was performed in accordance with relevant guidelines/regulations. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the ethics committee of the institution Comissão de Ética para Análise de Projetos de Pesquisa (CAPPesq n° 0282/11). Informed consent forms were obtained from all subjects and signed prior to the participation of all patients in the study by the patients, or by the parents or guardians when participants were under 18 years of age or unable to provide informed consent.

Genomic DNA extraction was performed using 4 mL of peripheral blood with EDTA anticoagulant and the QIAamp DNA Blood Midi Kit (Qiagen, Valencia, California). DNA samples were investigated by MLPA with the P036, P064, P070, P029, P250 kits.

The kits P036 and P070 were used for the investigation of CNVs in subtelomeric regions, kit P064 was used for detection of more common microdeletions or duplications, kit P029 was used for detection of CNVs within the critical region of Williams-Beuren syndrome (7q11.23), and kit P250 was implemented for detection of CNVs in the critical region of DiGeorge syndrome (22q11.2). MLPA was conducted according to the manufacturer's recommendations (MRC-Holland®, Amsterdam, the Netherlands).

Results were considered altered when the relative peak was lower than 0.75 (deletion) or higher than 1.25 (duplication) when compared to the control results. Altered results were compared to databases of genomic variants (DGV) [http://projects.tcg.ca/variation/] and DECIPHER (www.decipher.com).

Atypical finds by MLPA in selected cases were investigated using array techniques. In five cases, array assays were performed by CytoScan™ Affymetrix® (Santa Clara, California, USA); in three cases, the CGH-array Agilent SurePrint G3 human genome microarray 180 K (Agilent Technologies, Santa Clara, California, USA) was used; and in six cases, HumanCytoSNP-12 BeadChip (Illumina Inc., San Diego, California) was performed.

Table 3. Comparison between MLPA vs. array results performed on the same patient.
Analysis of the variants was performed in accordance with the Database of Genomic Variants and the Database of Genomic Variation and Phenotype in Humans Using Ensembl Resources (DECIPHER).

Patients evaluated by the CGH-array Agilent SurePrint G3 human genome microarray 180 K had results analyzed in collaboration with the Cytogenetic and Cytogenomic Laboratory of the Faculdade de Medicina da Universidade de Coimbra – Portugal (grant FAPESP BEPE n° 2012/25247-6). The others patients were studied in cooperation with the Cytogenomic Laboratory (HC-FMUSP).

All data generated or analyzed during this study are included in this published article.

References
1. LeJeune, J., Turpin, R. & Gautier, M. Chromosomal diagnosis of mongolism. Arch Fr Pediatr. 16, 962–963 (1959).
2. Pinto, D., Marshall, C., Feuk, L. & Scherer, S. W. Copy-number variation in control population cohorts. Hum Mol Genet. 2, 168–173 (2007).
3. Miller, D. T. et al. Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies. American Journal of Human Genetics. 86, 749–764 (2010).
4. Liu, P., Carvalho, C. M., Hastings, P. J. & Lupski, J. R. Mechanisms for recurrent and complex human genomic rearrangements. Curr Opin Genet Dev. 22, 211–220 (2012).
5. Carvalho, C. M. et al. Complex rearrangements in patients with duplications of MECP2 can occur by fork stalling and template switching. Hum Mol Genet. 18, 2188–2203 (2009).
6. Henrichsen, C. N., Chaignat, E. & Reymond, A. Copy number variants, diseases and gene expression. Hum Mol Genet. 18, 1–8 (2009).

Figure 2. SNP-array showing duplication 5q34q35.3 (160,148,716–180,712,253)x3.
7. Stankiewicz, P. & Beaudet, A. L. Use of array CGH in the evaluation of dysmorphology, malformations, developmental delay, and idiopathic mental retardation. *Curr Opin Genet Dev. 17*, 182–192 (2007).
8. Krantz, I. D. & Spinner, N. B. Novel microdeletion syndromes. *Am J Med Genet C Semin Med Genet. 145*, 322–326 (2007).
9. van Karnebeek, C. D., Jansweijer, M. C., Leenders, A. G., Offringa, M. & Hennekam, R. C. Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. *Eur J Hum Genet. 13*, 6–25 (2005).
10. Jehee, F. S. et al. Using a combination of MLPA kits to detect chromosomal imbalances in patients with multiple congenital anomalies and mental retardation is a valuable choice for developing countries. *Eur J Med Genet. 54*, 425–432 (2011).
11. Boggula, V. R. et al. Clinical utility of multiple ligation-dependent probe amplification technique in identification of aetiology of unexplained mental retardation: a study in 203 Indian patients. *Indian J Med Res. 139*, 66–75 (2014).
12. Resta, N. & Memo, L. Chromosomal microarray (CMA) analysis in infants with congenital anomalies: when is it really helpful? *J Matern Fetal Neonatal Med. 25*, 124–126 (2012).
13. Freeman, J. L. et al. Copy number variation: new insights in genome diversity. *Genome Res. 16*, 949–961 (2006).
14. de Ravel, T. J. et al. Molecular karyotyping of patients with MCA/SMR: the blurred boundary between normal and pathogenic variation. *Cytogenet Genome Res. 115*, 225–230 (2006).
15. Kirby, R. S. The prevalence of selected major birth defects in the United States. *Semin Perinatol. 41*, 338–344 (2017).
16. Monteiro, R. A. C. et al. Major Contribution of Genomic Copy Number Variation in Syndromic Congenital Heart Disease: The Use of MLPA as the First Genetic Test. *Mol Syndromol. 8*, 227–235 (2017).
17. Shoukier, M. et al. Array CGH in patients with developmental delay or intellectual disability: are there phenotypic clues to pathogenic copy number variants? *Clin Genet. 83*, 53–65 (2013).
18. Ledbetter, D. H. & Martin, C. L. Cryptic telomere imbalance: a 15-year update. *Am J Med Genet C Semin Med Genet. 145*, 327–334 (2007).
19. Bergemann, A. D., Cole, F. & Hirschhorn, K. The etiology of Wolf-Hirschhorn syndrome. *Trends Genet. 21*, 188–195 (2005).
20. Rodrigue, L. et al. Screening for subtelomeric chromosome alteration in a consecutive series of newborns with congenital defects. *Clin Dysmorphol. 17*, 5–12 (2008).
21. Robinion, W. P. et al. Somatic segregation errors predominantly contribute to the gain or loss of a paternal chromosome leading to uniparental disomy for chromosome 15. *Clin Genet. 57*, 349–358 (2000).
22. Christofolini, D. M. et al. Subtelomeric rearrangements and copy number variations in people with intellectual disabilities. *Int J Disabil Dev Disabil. 54*, 938–942 (2010).
23. De Vries, B. B., Winter, R., Schinzel, A. & van Ravenswaaij-Arts, C. Telomeres: a diagnosis at the end of the chromosomes. *J Med Genet. 40*, 385–398 (2003).
24. Ravnan, J. B. et al. Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities. *J Med Genet. 43*, 478–489 (2006).
25. Pohovska, L. M., Dumic, K. K., Odak, L. & Barisic, I. Multiplex ligation-dependent probe amplification workflow for the detection of submicroscopic chromosomal abnormalities in patients with developmental delay/intellectual disability. *Mol Cytogenet. 6*, 7 (2013).
26. Hochstenbach, R. et al. Array analysis and karyotyping: Workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands. *Eur J Med Genet. 52*, 161–169 (2009).
27. Edelmann, L. & Hirschhorn, K. Clinical utility of array CGH for the detection of chromosomal imbalances associated with mental retardation and multiple congenital anomalies. *Ann N Y Acad Sci. 1151*, 157–166 (2009).
28. Slavotinek, A. M. Novel microdeletion syndromes detected by chromosome microarrays. *Hum Genet. 124*, 1–17 (2008).
29. Siggberg, L. et al. High-resolution SNP array analysis of patients with developmental disorder and normal array CGH results. *BMC Med Genet. 13*, 84 (2012).
30. Vissers, L. E., de Vries, B. B. & Veltman, J. A. Genomic microarrays in mental retardation: from copy number variation to pathogenic copy number variants? *Clin Genet. 83*, 53–65 (2013).
31. Manning, M. & Hudgins, L. Professional Practice and Guidelines Committee. Array-based technology and recommendations for 30. Vissers, L. E., de Vries, B. B. & Veltman, J. A. Genomic microarrays in mental retardation: from copy number variation to gene, from idiopathic mental retardation and multiple congenital anomalies. *Ann N Y Acad Sci. 1151*, 182–192 (2007).
32. Feuk, L., Marshall, C. R., Wüttke, R. F. & Scherer, S. W. Structural variants: changing the landscape of chromosomes and design of disease studies. *Hum Mol Genet. 15*, 57–66 (2006).
33. Dutra, R. L. et al. Rare genomic rearrangement in a boy with Williams-Beuren syndrome associated to XYY syndrome and intriguing behavior. *Am J Med Genet A. 167*, 3197–3203 (2015).
34. Honjo, R. S. et al. Atypical deletion in Williams-Beuren syndrome critical region detected by MLPA in a patient with supravalvular aortic stenosis and learning difficulty. *J Genet Genomics. 39*, 571–574 (2012).
35. Schaaf, C. P., Scott, D. A., Wiszniewska, J. & Beaudet, A. L. Identification of incestuous parental relationships by SNP-based DNA microarrays. *Lancet. 377*, 555–556 (2011).

Acknowledgements

We thank the patients and their respective families for the participation in this study. This study was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) n° 2008/58238-4, 2009/53864-7, 2009/53105-9 and 2014/11572-8 from Chong Ae Kim, Ministério de Amparo à Pesquisa do Estado de São Paulo (FAPESP) – n° 2008/53105-9 and 2014/11572-8 from Leslie Domenici Kulikowski and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) – n° 2009/53105-9 and 2012/25247-6 from Roberta Le Lis Dutra.

Author Contributions

Evaluating the patients (Ceroni J.R.M., Honjo R.S., Llerena J.C. Jr, Acosta A.X., Medeiros P.F.V., Galera M.F., Piazzone F.B., Bertola D.R., Kim C.A.); writing the manuscript (Ceroni J.R.M., Dutra R.L.), reviewing of the manuscript (Honjo R.S., Kulikowski L.D., Kim C.A.); performing M.L.P.A. and array studies (Dutra R.L., Zanardo E.A., Dias A.T., Novo-Filho G.M., Montenegro M.M., Madia F.A.R., de Melo J.B., Kulikowski L.D.).

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018